


## SYMPTOM: PAIN

### **PATIENT UNABLE TO SWALLOW AND NOT ALREADY ON REGULAR STRONG OPIOIDS? (e.g. no regular morphine, oxycodone or fentanyl)**

If the patient is known to be intolerant to morphine or morphine not effective,  
**SEEK SPECIALIST ADVICE**



### **KEY MESSAGES – PAIN**

- Consider and eliminate reversible causes for pain (constipation, urinary retention, spiritual and psychological causes)
- Would a pain chart be of benefit?
- Use '*Stockport Pain and Symptom Control Guidelines*' Opioid conversion charts for extra support
- For specialist advice contact Palliative Care Team or St Ann's Helpline (see attached sheet)

**If morphine requirement via csci is greater than 600mg over 24 hours, seek specialist advice**

## SYMPTOM: PAIN

### PATIENT TAKING REGULAR ORAL MORPHINE BECOMES UNABLE TO SWALLOW?

If the patient is taking oral **oxycodone** seek specialist advice when commencing a continuous subcutaneous infusion

Is pain controlled on current dose?

NO

YES

#### Commence CSCI via a Syringe Pump

- Convert the dose of oral morphine to the s/c equivalent (see key messages below)
- Consider increasing total 24 hour dose of s/c morphine by 30-50%.
- Give the increased total 24 hour dose of s/c morphine via syringe pump over 24 hours
- Calculate new breakthrough dose (see key messages below)

#### Commence CSCI via a Syringe Pump

- Convert the dose of oral morphine to the s/c equivalent (see key messages below)
- Calculate breakthrough dose in case required (see key messages below)

#### Review Pain at Each Visit

- Is morphine effective?
- If the patient needed more than 2 PRN doses in 24 hours consider if the 24 hour csci dose needs increasing
- Recalculate csci dose by adding PRN doses to amount in csci (Do not increase by more than 50%)
- If patient needs more than 4 PRN doses or morphine not effective **seek specialist advice**

#### KEY MESSAGES - PRESCRIBING SUBCUTANEOUS MORPHINE

- To calculate the dose of s/c morphine, divide total dose of oral morphine by 2
- To calculate the breakthrough dose of morphine divide total 24 hour dose of s/c morphine by 6 and prescribe this dose 4 hourly s/c PRN (do not forget to include opioid patches in your calculation)
- Use '*Stockport Pain and Symptom Control Guideline*' opioid conversion charts for extra support

**If morphine requirement via CSCI is greater than 600mg over 24 hours, seek specialist advice**

## **SYMPTOM: PAIN**

**PATIENT USING FENTANYL PATCHES AND IS NOW UNABLE TO SWALLOW**

### **IMPORTANT**

**CONTINUE TO USE AND CHANGE PATCH EVERY 72 HOURS AS PREVIOUSLY PRESCRIBED**

#### **Pre-Emptive Prescribing**


- Use S/C morphine for breakthrough pain
- Calculate or consult conversion chart as a guide (see below) for the PRN dose of s/c morphine that is relevant for the strength of patch
- Prescribe the dose 2 - 4 hourly PRN in case pain occurs

**If pain not controlled or if needing more than 2 PRN doses are required over 24 hours seek specialist advice**  
(See attached sheet)

<b>Fentanyl Transdermal (microgram/hour)</b>	<b>Subcutaneous morphine PRN dose (2 – 4 hourly PRN)</b>
12	2.5mgs
25	5mgs
37	7.5mgs
50	10mgs
62	12.5mgs
75	15mgs
100	20mgs

**(Stockport Palliative Care Pain and Symptom Control Guidelines – 4<sup>th</sup> Edition)**


## IS THE PATIENT EXPERIENCING TERMINAL RESTLESSNESS AND / OR AGITATION?



### KEY MESSAGES – TERMINAL RESTLESSNESS AND AGITATION

- Document that reversible causes of agitation have been considered (pain, constipation, urinary retention, overheating, infection, nicotine withdrawal, high calcium levels)
- Review effectiveness of management at every visit, if **not** effective, **seek specialist advice**
- Consider adding any PRN doses given in previous 24 hours to syringe pump dose
- The PRN dose of midazolam should be the amount in the syringe pump divided by 6


## ARE RESPIRATORY TRACT SECRETIONS PRESENT?



### KEY MESSAGES – TERMINAL RESTLESSNESS AND AGITATION

- Treatment must be commenced at **onset** of secretions. Medication will prevent new secretions being produced but will not remove secretions already present
- The BNF lists this antimuscarinic drug as glycopyrronium bromide. Ampoules are labeled as both glycopyrronium bromide and glycopyrrolate
- Terminal respiratory secretions may be most upsetting for family and those close to the patient. Discussion of these symptoms with them is important.
- Palliative treatment with antibiotics may be appropriate if they are likely to help reduce purulent secretions and increase the comfort of the patient


## IS THE PATIENT BREATHLESS?



### KEY MESSAGES – BREATHLESSNESS

- Treatments for reversible causes of breathlessness include; bronchodilators, diuretics, and antibiotics
- Simple measures such as a calm environment, a fan or open window can be just as effective as medication
- If the patient is taking regular opiates or benzodiazepines **seek specialist advice**

## IS THE PATIENT EXPERIENCING NAUSEA AND / OR VOMITING?



### KEY MESSAGES – NAUSEA AND VOMITING

- Patients with complete bowel obstruction and nausea or vomiting should not receive metoclopramide
- Metoclopramide and cyclizine should not be prescribed simultaneously
- Cyclizine should be diluted with water for injection to prevent crystallization
- Simple measures such as treating constipation and keeping the patient away from strong food smells may also help